Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Case Studies In FDA's Regulatory Interpretation Of Clinical Trials

Oct 03 2016

• By Bridget Silverman

Related Content

<em>Erivedge</em> Efficacy Overcomes Limitations Of Single-Arm Study

Nov 01 2012

FDA Offers Possible Reasons For Vectibix Failure To Show Survival Benefit

Mar 15 2007

FDA Changed Course On <em>Zontivity </em>Because Of Skepticism Of Subgroups At High Levels

Sep 01 2014

The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible

Mar 01 2011

<em>Brilinta</em> Review Sparks War Of Words Between FDA Cardio-Renal Division’s Marciniak, Stockbridge

Jan 01 2012

Multiple Aspirin Dose Analyses Reassured FDA On <em>Brilinta</em>’s U.S. Efficacy

Jan 01 2012

<em>Firazyr</em> Efficacy Findings Were Muddied By Choice Of Comparator

Feb 01 2012

<em>Kalydeco</em> Passed FDA’s Approval Test With The Help Of A Failed Study

Jun 19 2012

FDA Used Regulatory Loophole To Save Novartis' <em>Farydak</em>

Aug 17 2015

A Cautious Guide To The Interpretation Of Clinical Trials From NEJM

Oct 03 2016

Patient Voices Swayed FDA's <em>Imlygic</em> Review Team

Apr 25 2016

<em>Fulyzaq</em> Review Shows FDA Adapting Smoothly To Adaptive Trial Design

May 22 2013

Additional Topics

Clinical Trials Regulation BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window